| Jeffrey S. Garbis, M.D., F.A.C.G. |
|
| Education: |
| American University, 1968; B.S. |
| University of Guadalajara, 1972; M.D. |
| University of Maryland Hospital, 1973, Trac V |
| Maryland General Hospital/University of Maryland, 1974- 1975;
Internship |
| Maryland General Hospital University of Maryland, 1975-1977:
Residence |
| Fellowship in Gastroenterology, Maryland General Hospital under
Howard Raskin, M.D., Chief of Gastroenterology, Baltimore, Maryland.
Program affiliated with the University of Maryland, 1977-1979 |
| Certification: |
| Federal Licensing Examination |
| American Board of Internal Medicine |
| American Board of Gastroenterology |
| Advanced Cardiac Life Support Certification |
| Experience: |
Active Staff, Washington Adventist Hospital
Laurel Regional Hospital
Howard County General |
| Chief, Gastroenterology subdivision, Washington Adventist Hospital,
1984 to 1997 |
| Memberships: |
Member, American Society of Gastroenterology and Endoscopy
Fellow, American College of Gastroenterology
William Clark Society of Washington
Medical and Chirurgical Faculty of the State of Maryland
Member, Ileitis & Colitis Foundation
American Gastroenterology Association
Maryland Society of G.I. Endoscopy |
| Committees: |
Pharmacia and Therapeutic Committee
Infectious Disease Committee
Quality Assurance Committee |
| Hospital Affiliations: |
Washington Adventist Hospital
Laurel Regional Hospital
Howard County General Hospital |
| Research Facility: |
Maryland Digestive Disease Research LLC, Co-Owner
7350 Van Dusen Road Suite 360
Laurel, MD 20707
Investigator 1997-present |
| Research Trials: |
| Principal Investigator |
2003 A Twelve-Week, Randomized, Double Blind, Placebo-Controlled,
Parallel0Group Study to Assess the Safety and Efficacy of a 0.5
mg QD, 1 mg QD and 1 mg BID of XXX in Female subjects with Severe
Diarrhea-predominant IBS Who Have Failed Conventional Therapy
2002 Double-Blind, Placebo-Controlled, Randomized, Multicenter
Study to Investigate the safety and efficacy of 2 mg of TID
of XXX Over 12 Weeks followed by a 4-week Rerandomized Treatment
Period in Diarrhea-Predominant Irritable Bowel Syndrome Subjects
2001-2002
Double-Blind, Randomized, Placebo-Controlled Multicenter Study
to Investigate the Long Term Safety 2 mg PRN of XXX in Diarrhea-Predominant
Irritable Bowel Syndrome Subjects
|
| Sub-Investigator |
A Randomized, Placebo-Controlled Trial of XXX for treatment
of Ulcerative Colitis
Dose Comparison Study of XXX + XXX for Patients with Chronic
Hepatitis C Who Have Not Responded to Standard XXX + XXX
A comparative Efficacy and Safety Study of XXX Delayed-Release
Capsules Versus Placebo for the prevention of Gastric Ulcers
Associated with Daily NSAID Use in Patients at Risk
Endoscopic Study of Gastro duodenal Effects in Patients with
Rheumatoid Arthritis
|
| Other Application: |
Maryland Digestive Disease Center
7350 Van Dusen Rd. Suite 210
Laurel, MD 20707
Ambulatory Endoscopy Center of Maryland
7350 Van Dusen Rd. Suite 230
Laurel, MD 20707
|
